HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism.

AbstractBACKGROUND AND PURPOSE:
The benefits and safety of thrombolytic therapy was studied in patients with acute brain embolism.
METHODS:
We intravenously administered recombinant tissue plasminogen activator (20-30 MU for 1 hour) to 10 patients with acute (less than 6 hours) brain embolism and examined the neurological outcomes in relation to the findings on computed tomography and angiography.
RESULTS:
The symptoms ameliorated in four patients within 24 hours after onset, and reopening of the occluded arteries occurred in two of the patients immediately after recombinant tissue plasminogen activator infusion. On the initial computed tomographic scan (less than 3 hours), four patients had already demonstrated early indications of brain ischemia, that is, an obscure margin of the lentiform nuclei, reduced tissue attenuation, or effacement of cortical sulci. These patients failed to demonstrate reopening of the occluded arteries, and one developed a massive brain hemorrhage with clinical deterioration. Of the remaining six patients, two obtained clinical improvement with recanalization soon after the therapy and demonstrated little to slight hemorrhagic complications. The outcomes at 1 month were favorable in five patients and poor in three; death occurred in two.
CONCLUSIONS:
Thrombolytic therapy with recombinant tissue plasminogen activator may be safe and effective when there are no early computed tomographic findings within 3 hours from the onset of embolic stroke.
AuthorsY Okada, S Sadoshima, H Nakane, H Utsunomiya, M Fujishima
JournalStroke (Stroke) Vol. 23 Issue 1 Pg. 20-3 (Jan 1992) ISSN: 0039-2499 [Print] United States
PMID1731415 (Publication Type: Journal Article)
Chemical References
  • Recombinant Proteins
  • Tissue Plasminogen Activator
Topics
  • Adult
  • Aged
  • Humans
  • Intracranial Embolism and Thrombosis (diagnostic imaging, drug therapy)
  • Middle Aged
  • Recombinant Proteins (therapeutic use)
  • Tissue Plasminogen Activator (therapeutic use)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: